Comparative bioavailability of sustained-release morphine sulfate capsules versus pellets

Clinical Drug Investigation

Volumn 14, Issue 2, 1997, Pages 137-145

  Broomhead, Alan ^a   West, Raelene ^a   Kadirgamanathan, Gaithry ^a   Knox, Kaye ^a   Krueger, Don ^b   Malick, Jeffrey ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; MORCAP SR; MORPHINE SULFATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG PELLET; DRUG RELEASE; ELECTROCHEMICAL DETECTION; FEMALE; FOOD INTAKE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICS; SUSTAINED RELEASE PREPARATION; VERTIGO;

EID: 0030861950     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714020-00008     Document Type: Article

References (18)

1. Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol™, MST Continus® and morphine solution in cancer patients; pharmacokinetic aspects of morphine and morphine metabolites. In: Gebhart GF, Hammond DL, Jensen TS. editors. Progress in pain research and management. Seattle: IASP Press, 1994: 631-43
2. Maccarrone C, West RJ, Broomhead AF, et al. Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation. Drug Invest 1994; 7 (5): 262-74
3. Plummer JL, Cherry DA, Gourlay GK, et al. A comparison of Kapanol (a new sustained-release morphine formulation). MST Continus® and morphine solution in cancer patients: pharmacodynamic aspects [abstract no. 1000]. 7th World Congress on Pain, August 1993; Paris
4. Toner G, Cramond T, Bishop J, et al. Randomized double blind, phase III crossover study of a new sustained-release oral morphine formulation, Kapanol capsules [abstract 1001]. 7th World Congress on Pain, August 1993; Paris
5. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty four hourly Kapanol™ compared to twelve hourly MS Contin® in the treatment of severe cancer pain. Pain 1997; 69 (3): 295-302
6. Broomhead AF, Kerr R, Tester W, et al. Comparison of a once- day sustained-release oral morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage. In press
7. Twycross R, Lack S. Oral morphine in advanced cancer. 2nd ed. Buckinghamshire: Beaconsfield Publishers Ltd, 1989
8. Walsh D. Palliative care: management of the patient with advanced cancer. Semin Oncol 1992; 21 Suppl. 7: 100-6
9. World Health Organization. Cancer pain relief and palliative care. Report of a WHO Expert Committee. WHO Technical Report Series 804, WHO, Geneva, 1990
10. Bonica JJ, Ekstrom JL. Systemic opioids for the management of cancer pain: an updated review. In: Bendetti C, Chapman CR, Giron G, editors. Advances in pain research and therapy. Vol. 14, New York: Raven Press, 1990: 425-46
11. Jones R, Hale E, Talomsin L, et al. Kapanol™ capsules. Pellet formulation provides alternative methods of administration of sustained-release morphine sulfate. Clin Drug Invest 1996; 12 (2): 88-93
12. Todd RD, Muldoon SM, Watson RL. Determination of morphine in cerebrospinal fluid and plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1982; 232: 101-10
13. Schuirmann DL. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 715: 657-80
14. US Food and Drug Administration. Guidelines for oral extended (controlled) release dosage forms in vivo bioequivalence and in vitro dissolution testing. Rockville, Maryland. Division of Bioequivalence, Office of Generic Drugs; Center for Drug Evaluation and Research, US Food and Drug Administration; September, 1993
15. Portenoy RK. General design issues. In: Max M, Portenoy RK, Laska L, editors. Advances in pain research and therapy. Vol. 18, New York: Raven Press, 1991: 233-66
16. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4
17. Cockburn J, Reid AL, Bowman JA, et al. Effects of intervention on antibiotic compliance in patients in general practice. Med J Aust 1987; 147: 324-8
18. Broomhead A, West R, Eglinton L, et al. Comparative single dose pharmacokinetics of sustained-release and modified- release morphine sulfate capsules under fed and fasting conditions. Clin Drug Invest 1997; 13 (3): 1-9